![Paul Herzich](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Paul Herzich
Directeur Technique/Scientifique/R&D chez SOLID BIOSCIENCES INC.
Fortune : 49 742 $ au 31/05/2024
Postes actifs de Paul Herzich
Sociétés | Poste | Début | Fin |
---|---|---|---|
SOLID BIOSCIENCES INC. | Directeur Technique/Scientifique/R&D | 01/12/2022 | - |
Historique de carrière de Paul Herzich
Anciens postes connus de Paul Herzich
Sociétés | Poste | Début | Fin |
---|---|---|---|
Aavantibio, Inc.
![]() Aavantibio, Inc. BiotechnologyHealth Technology Aavantibio, Inc. engages in developing gene therapies. The company was founded by Barry Byrne and Manuela Corti and is headquartered in Gainesville, FL. | Directeur Technique/Scientifique/R&D | 01/04/2021 | 01/12/2022 |
BRIDGEBIO PHARMA, INC. | Corporate Officer/Principal | 01/08/2020 | 01/04/2021 |
LOGICBIO THERAPEUTICS, INC. | Corporate Officer/Principal | 01/01/2018 | 01/07/2019 |
Bamboo Therapeutics, Inc.
![]() Bamboo Therapeutics, Inc. BiotechnologyHealth Technology Bamboo Therapeutics, Inc. develops gene therapy products for central nervous system and neuromuscular diseases. Its therapeutic platform is based on the use of Adeno-associated virus as a gene therapy vehicle. The company’s proprietary technologies include chimeric vectors, self-complementary vectors, and dual glycan receptor. It focuses on the treatment of Duchenne muscular dystrophy, giant axonal neuropathy, Friedreich ataxia, and Canavan disease. Bamboo Therapeutics was founded by Richard Jude Samulski, Sheila A. Mikhail, Josh Grieger, Xiao Xiao, and Paola Leone in December 2014 and is headquartered in Chapel Hill, NC. | Corporate Officer/Principal | 01/08/2016 | 01/01/2018 |
Csl Seqirus | Corporate Officer/Principal | 01/12/2007 | 01/07/2015 |
Formation de Paul Herzich
Rutgers State University of New Jersey | Undergraduate Degree |
Poole College of Management | Masters Business Admin |
Statistiques
Internationale
Etats-Unis | 8 |
France | 2 |
Opérationnelle
Corporate Officer/Principal | 4 |
Chief Tech/Sci/R&D Officer | 2 |
Masters Business Admin | 1 |
Sectorielle
Health Technology | 6 |
Consumer Services | 3 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 2 |
---|---|
SOLID BIOSCIENCES INC. | Health Technology |
BRIDGEBIO PHARMA, INC. | Health Technology |
Entreprise privées | 4 |
---|---|
Bamboo Therapeutics, Inc.
![]() Bamboo Therapeutics, Inc. BiotechnologyHealth Technology Bamboo Therapeutics, Inc. develops gene therapy products for central nervous system and neuromuscular diseases. Its therapeutic platform is based on the use of Adeno-associated virus as a gene therapy vehicle. The company’s proprietary technologies include chimeric vectors, self-complementary vectors, and dual glycan receptor. It focuses on the treatment of Duchenne muscular dystrophy, giant axonal neuropathy, Friedreich ataxia, and Canavan disease. Bamboo Therapeutics was founded by Richard Jude Samulski, Sheila A. Mikhail, Josh Grieger, Xiao Xiao, and Paola Leone in December 2014 and is headquartered in Chapel Hill, NC. | Health Technology |
LogicBio Therapeutics, Inc.
![]() LogicBio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology LogicBio Therapeutics, Inc. engages in the development of a genome editing technology platform. It focuses on the commercialization of GeneRide, which enables the site-specific integration of a therapeutic transgene without nucleases or exogenous promoters by harnessing the native process of homologous recombination. Its pipeline includes LB-001, LB-301 and LB-401. The company was founded by Mark A. Kay, Leszek Lisowski, and Adi Barzel in August 2014 and is headquartered in Lexington, MA. | Health Technology |
Aavantibio, Inc.
![]() Aavantibio, Inc. BiotechnologyHealth Technology Aavantibio, Inc. engages in developing gene therapies. The company was founded by Barry Byrne and Manuela Corti and is headquartered in Gainesville, FL. | Health Technology |
Csl Seqirus |
- Bourse
- Insiders
- Paul Herzich
- Expérience